Elan shares down after patient develops brain infection

Shares in Elan are down more than 4% after another patient taking the multiple sclerosis drug Tysabri developed a potentially deadly brain infection.

It is the fifth such case since the drug was reintroduced to the market under strict safety warnings in July 2006.